Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. grew its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) by 21.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,628 shares of the company’s stock after purchasing an additional 285 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Apogee Therapeutics were worth $94,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of APGE. EntryPoint Capital LLC grew its holdings in Apogee Therapeutics by 44.7% during the 1st quarter. EntryPoint Capital LLC now owns 1,997 shares of the company’s stock valued at $133,000 after buying an additional 617 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in Apogee Therapeutics during the 2nd quarter worth about $143,000. Kennedy Capital Management LLC acquired a new position in Apogee Therapeutics in the 1st quarter valued at about $212,000. Arizona State Retirement System lifted its holdings in Apogee Therapeutics by 4.5% in the 2nd quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock valued at $236,000 after purchasing an additional 258 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Apogee Therapeutics by 26.3% during the 2nd quarter. Principal Financial Group Inc. now owns 6,442 shares of the company’s stock worth $253,000 after purchasing an additional 1,340 shares during the last quarter. 79.04% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Apogee Therapeutics

In other news, CEO Michael Thomas Henderson sold 40,000 shares of the stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $40.62, for a total value of $1,624,800.00. Following the completion of the sale, the chief executive officer now owns 1,434,487 shares of the company’s stock, valued at $58,268,861.94. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Apogee Therapeutics news, insider Carl Dambkowski sold 7,335 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $40.67, for a total value of $298,314.45. Following the completion of the transaction, the insider now owns 287,458 shares in the company, valued at $11,690,916.86. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $40.62, for a total transaction of $1,624,800.00. Following the sale, the chief executive officer now owns 1,434,487 shares in the company, valued at $58,268,861.94. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 146,665 shares of company stock valued at $7,058,635 over the last ninety days. Corporate insiders own 36.10% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Wedbush reissued an “outperform” rating and issued a $87.00 price objective on shares of Apogee Therapeutics in a research report on Friday, October 25th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $78.50.

Apogee Therapeutics Stock Performance

Apogee Therapeutics stock opened at $56.30 on Tuesday. Apogee Therapeutics, Inc. has a 1 year low of $14.19 and a 1 year high of $72.29. The firm has a 50 day moving average price of $53.28 and a 200 day moving average price of $48.43. The company has a market cap of $2.53 billion, a price-to-earnings ratio of -27.20 and a beta of 2.94.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.60) EPS for the quarter, hitting analysts’ consensus estimates of ($0.60). Sell-side analysts predict that Apogee Therapeutics, Inc. will post -2.57 EPS for the current year.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.